IDSA GUIDELINES Bundle (free trial)

Ventriculitis and Meningitis

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/810891

Contents of this Issue

Navigation

Page 5 of 15

6 Treatment Empiric Antimicrobials ➤ Vancomycin plus an anti-pseudomonal β-lactam (such as cefepime, ceftazidime or meropenem) is recommended as empiric therapy for healthcare-associated ventriculitis and meningitis. Choice of the empiric β-lactam agent should be based on local in vitro susceptibility patterns (S-L). ➤ In seriously ill adult patients with healthcare-associated ventriculitis and meningitis, the vancomycin trough concentration should be maintained at 15–20 μg/mL in those receiving intermittent bolus administration (S-L). ➤ For patients with healthcare-associated ventriculitis and meningitis who have experienced anaphylaxis to β-lactam antimicrobial agents and in whom meropenem is contraindicated, aztreonam or ciprofloxacin is recommended for gram-negative coverage (S-L). ➤ For patients with healthcare-associated ventriculitis and meningitis who are colonized or infected elsewhere with a highly antimicrobial- resistant pathogen, adjusting the empiric regimen to treat for this pathogen is recommended (S-L). Specific Antimicrobials ➤ For treatment of infection caused by methicillin-susceptible Staphylococcus aureus, nafcillin or oxacillin is recommended (S-M). If the patient cannot receive β-lactam agents, the patient can be desensitized or may receive vancomycin as an alternative agent (W-M). ➤ For treatment of infection caused by methicillin-resistant S. aureus (MRSA), vancomycin is recommended as first line therapy (S-M), with consideration for an alternative antimicrobial agent if the vancomycin MIC is ≥1 μg/mL (S-M). ➤ For treatment of infection caused by coagulase-negative staphylococci, the recommended therapy should be similar to S. aureus and based on in vitro susceptibility testing (S-M). ➤ If the staphylococcal isolate is susceptible to rifampin, this agent may be considered in combination with other antimicrobial agents for staphylococcal ventriculitis and meningitis (W-L). Rifampin is recommended as part of combination therapy for any patient with intracranial or spinal hardware such as a CSF shunt or drain (S-L).

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Ventriculitis and Meningitis